In a report from the Associated French Press, Pfizer head Albert Bourla claimed a vaccine may come as early as the end of October, acknowledging the date requires an ideal path.
"If things go well, and the stars are aligned," said Bourla, "we will have enough evidence of safety and efficacy so that we can... have a vaccine around the end of October," Bourla stated optimism the vaccine could be ready between then and the end of the year.
Meanwhile, the vast majority of vaccine manufacturers have reported development efforts rarely extending beyond the Phase I/II stage, where the last phase is a lengthy and complicated process for safety and testing. Despite this, some messaging has been counterintuitive, namely the aggressive quantities and timelines of the Trump administration's "Project Warpspeed" expecting 300M vacccines to become available by "Early January"
We are likely to see treatments coming much earlier, with Russia already announcing they'll have an effective COVID-19 treatment this month.
The more intuitive efforts to speed up vaccine development include the intentional infecting of healthy individuals with COVID-19 as a means to test the vaccine. To accelerate the recruitment effort, the website 1 Day Sooner was launched where it has already recruited 27 thousand participants.
Meanwhile experts like Dr. Paul Offit, Director of the Vaccine Education Center at the Children's Hospital of Philadelphia say current reports of vaccine advancement are overblown.
Reports some experts claim exaggerate the success of early studies have taken a significantly positive effect on stock prices, especially Moderna Pharmaceuticals, whose stock price more than tripled since April.